NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

NCT06785675

Active Not RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Hidradenitis Suppurativa

Interventions: Secukinumab

Countries: United Arab Emirates

This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in real-world settings, especially in the Gulf Region.

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3)
* Male or Female adult patients ≥ 18 years of age at the time of data collection
* Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent)
* Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion.
* Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion.
* Agreed to sign an informed consent to be able to fill in the questionnaires.

Exclusion Criteria:

* Patients not fulfilling any of the abovementioned inclusion criteria.
* Patient's refusal to be included in the study or refusal to sign the informed consent.

Locations (4)

Al Ain Abu Dhabi, United Arab Emirates, United Arab Emirates
Abu Dhabi, United Arab Emirates
Ras al-Khaimah, United Arab Emirates
Sharjah city, United Arab Emirates